RA Capital’s $150 M Surge in Hemab Common Stock Post‑IPO Signals Bullish Confidence Amid Clinical Milestones

Hemab Therapeutics Holdings Sees Surge in Insider Buying Amid IPO Momentum

Insider Buying Highlights Confidence in the Pipeline On May 4, 2026, RA Capital Management, L.P. – the investment arm of RA Capital Healthcare Fund – added over 6.2 million shares of Hemab Therapeutics Holdings (COAG) to its portfolio in a series of purchases at a weighted average price of $24.59‑$25.00. These transactions, reported under Form 4, followed the company’s recent IPO, which raised approximately $347 million. The volume of buying – more than 6 million shares – represents a sizeable portion of the company’s market cap of $1.17 billion and signals strong confidence from a professional investment manager.

Strategic Timing and Potential Impact on Share Liquidity The purchases occurred just days after the IPO, a period when the stock price hovered around $25, well below its 52‑week high of $36.61. By locking in shares at this level, RA Capital demonstrates willingness to hold during the early post‑market phase, which may provide a stabilizing effect on liquidity. Moreover, the timing suggests that the manager believes the IPO has already captured the most immediate upside, and that further upside will come as clinical milestones are achieved.

Implications for Other Investors and the Company’s Future The influx of institutional shares can help support the share price by adding depth to the market, potentially reducing volatility as the company moves forward with Phase 2 trials for HMB‑001 and HMB‑002. For retail investors, the activity may be a positive signal that professional managers see long‑term value beyond the initial IPO hype. However, insiders are also actively selling preferred shares, as shown by the series of preferred‑stock sales by Novo Holdings A/S on the same day. This contrast highlights a common post‑IPO pattern: buying common stock while divesting preferred equity that was issued at a higher valuation.

Balancing Optimism with Caution While the insider buying is encouraging, Hemab remains a clinical‑stage biotech with no commercial products yet. The company’s ability to secure future funding, navigate regulatory pathways, and achieve clinical milestones will ultimately determine whether the current share price reflects its true potential. Investors should watch for upcoming trial results and additional capital‑raising events, which will be critical checkpoints for the stock’s trajectory.